Dihydroorotate Dehydrogenase

DHODH

Dihydroorotate Dehydrogenase

Related Products

Dihydroorotate dehydrogenase (DHODH) is the fourth enzyme in the de novo pyrimidine biosynthesis pathway, serving as the catalyst to oxidize the dihydroorotate to orotic acid in the biosynthesis of uridine monophosphate (UMP). DHODH is a known target for autoimmune diseases as well as an important target for malaria.

Based on localization and electron acceptor, DHODHs have classified into two families: Family 1 members are soluble proteins localized to the cytosol, while family 2 members are membrane proteins localized to the inner mitochondrial membrane. Family 1 is further subdivided into family 1A and family 1B, which use fumarate and NAD⁺ (respectively) as electron acceptors. Family 2 DHODH enzymes use respiratory quinones as electron acceptors.

Dihydroorotate Dehydrogenase Related Products (103)
Antibodies (1)

By Effects:	Inhibitors (98) Agonists (2) Substrates (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-119453

Oxycinchophen	Inhibitor
Oxycinchophen exhibits anti-inflammatory and uricosuric activity. Oxycinchophen displaces urate from albumin, exhibits high affinity for the DNSA-binding site on the albumin molecule.

HY-135619

DHODH-IN-4	Inhibitor
DHODH-IN-4 (compound 17) is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor, with IC₅₀ values of 4 μM and 0.18 μM for PfDHODH and HsDHODH, respectively. DHODH-IN-4 (compound 17) possess antimalarial activity.

HY-147788

hDHODH-IN-9	Inhibitor
hDHODH-IN-9 (Compound 3k) is a potent inhibitor of hDHODH with an IC₅₀ of 0.34 μM. hDHODH-IN-9 demonstrates high cytotoxic activity against MCF-7 and A375 cells and good selectivity. hDHODH-IN-9 has the potential for the research of cancer diseases.

HY-163158

DHODH-IN-24	Inhibitor
DHODH-IN-24 (compound 16) is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 91 nM.

HY-146317

P1788	Inhibitor
P1788 is a dihydroorotate dehydrogenase (DHODH) inhibitor. P1788 induces DNA damage.

HY-B0083R

Leflunomide (Standard)	Inhibitor
Leflunomide (Standard) is the analytical standard of Leflunomide. This product is intended for research and analytical applications. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-100688R

ML390 (Standard)	Inhibitor
ML390 (Standard) is the analytical standard of ML390 (HY-100688). This product is intended for research and analytical applications. ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models.

HY-135662

DHODH-IN-34	Inhibitor
DHODH-IN-34 (Compound 21q) is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 13 nM. DHODH-IN-34 is promising for research of RNA viruses such as measles virus and chikungunya virus.

HY-104029R

Olorofim (Standard)	Inhibitor
Olorofim (Standard) is the analytical standard of Olorofim (HY-104029). This product is intended for research and analytical applications. Olorofim (F901318) selectively inhibits fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the pyrimidine biosynthesis pathway. Olorofim (F901318). Olorofim exhibits excellent activity against A. fumigatus and other Aspergillus spp..

HY-173354

hDHODH-IN-17	Inhibitor
hDHODH-IN-17 (Compound 10) is a human dihydroorotate dehydrogenase (hDHODH) inhibitor, with an IC₅₀ of 0.188 μM. hDHODH-IN-17 is in good agreement with the hDHODH activity pocket and interacted well with amino acid residues. hDHODH-IN-17 is the potential broad-spectrum antiviral agent.

HY-117908

DSM267	Inhibitor
DSM267 is a triazolopyrimidine inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH), with an IC₅₀ of 38 nM, while its IC₅₀ against human DHODH exceeds 100000 nM. DSM267 is used for the in vitro systematic screening and characterization of the resistance evolution pathways of Plasmodium falciparum to DHODH inhibitors.

HY-B0083S1

Leflunomide-¹³C₆	Inhibitor
Leflunomide-¹³C₆ (HWA486-¹³C₆) is ¹³C labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

HY-120462

Genz-669178	Inhibitor
Genz-669178 is an inhibitor for dihydroorotate dehydrogenase (DHODH) with IC₅₀ of 0.015-0.05 μM in Plasmodium spp.. Genz-669178 inhibits P. berghei, P. falciparum strains 3D7 and Dd2 with IC₅₀ of 0.068, 0.008 and 0.01 μM, respectively. Genz-669178 exhibits anti-malarial efficacy in P. berghei-infected mice with ED₅₀ of 13-21 mg/kg/day. Genz-669178 exhibits good pharmacokinetic characteristics in mice.

HY-108325S

Brequinar-d₃	Inhibitor
Brequinar-d₃ (DUP785-d₃) is deuterium labeled Brequinar. Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC₅₀ of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity.

HY-101813R

Laflunimus (Standard)	Inhibitor
Laflunimus (Standard) is the analytical standard of Laflunimus. This product is intended for research and analytical applications. Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor.

HY-169220S

RORγ/DHODH-IN-1	Inhibitor
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and DHODH inhibitor with IC₅₀ values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5).

HY-176280

SARS-CoV-2-IN-115	Inhibitor
SARS-CoV-2-IN-115 (Compound 3e) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-115 has potent antiviral activity against SARS-CoV-2 in infected Calu-3 cells (EC₅₀: 1.7  μM). SARS-CoV-2-IN-115 effectively inhibits the activity of human dihydroorotate dehydrogenase (HsDHODH) (IC₅₀: 1.5  μM). SARS-CoV-2-IN-115 preserves immune response without antiproliferative effects on CD4 T cells .

HY-114215

DSM-421	Inhibitor
DSM-421 is an orally active Dihydroorotate dehydrogenase inhibitor. DSM-421 has antiplasmodium activity.

HY-169222S

RORγ/DHODH-IN-2	Inhibitor
RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC₅₀ values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC₅₀ values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively.

HY-N6961R

Lapachol (Standard)	Inhibitor
Lapachol (Standard) is the analytical standard of Lapachol. This product is intended for research and analytical applications. Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Dihydroorotate Dehydrogenase

Dihydroorotate Dehydrogenase

Dihydroorotate Dehydrogenase Related Products (103)

Antibodies (1)

Dihydroorotate Dehydrogenase Related Products (103):